Gilead Sciences | Ativo Circulante



Current Assets Alterar Data
AbbVie USD 25.58B 2.2B 2024-12
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
ALKERMES USD 1.48B 63.7M 2025-03
Alnylam Pharmaceuticals USD 3.27B 27.03M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Eli Lilly USD 41.26B 8.52B 2025-03
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 18.08B 1.09B 2025-03
Glaxosmithkline GBP 17B 301M 2024-12
Incyte USD 3.23B 7.24M 2025-03
J&J USD 71.55B 15.66B 2025-03
Merck USD 35.5B 3.28B 2025-03
Moderna USD 6.77B 1.33B 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 45.86B 4.5B 2025-03
PTC Therapeutics USD 1.37B 83.98M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Sanofi 44.02B 1.43B 2025-03
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
United Therapeutics USD 3.94B 65.9M 2025-03
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Gilead Sciences Ativo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - May 2025.